Reference

Combinations of eszopiclone and O-desmethylvenlafaxine for treatment of menopause and mood, anxiety, and cognitive disorders

All Rights Reserved. Combinations of eszopiclone and O-desmethylvenlafaxine for treatment of menopause and mood, anxiety, and cognitive disorders. Caron, Judy; Wessel, Thomas; Lalji, Karim; Varney, Mark A. (Sepracor Inc., USA). PCT Int. Appl. WO 2007005961 A2 11 Jan 2007, 42pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2006-US26185 5 Jul 2006. PRIORITY: US 2005-697012P 6 Jul 2005. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 2 One aspect of the present invention relates to pharmaceutical compns.In this article, certain chemicals are used. Some of their cas registry numbers are 386750-22-7 and 93413-62-8 contg. 2 or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical compn. is a sedative eszopiclone. The second component of the pharmaceutical compn. is O-desmethylvenlafaxine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders. Thus, a capsule contained eszopiclone 3.0, O-Desmethylvenlafaxine succinate salt monohydrate 303.4, Avicel PH102 198.9, dibasic calcium phosphate 90.0, Croscarmellose sodium 6.0, colloidal silica 0.6, and Mg stearate 1.5 mg/unit. .